|
1
|
Brenner H, Kloor M and Pox CP: Colorectal
cancer. Lancet. 383:1490–1502. 2014. View Article : Google Scholar
|
|
2
|
Siegel R, DeSantis C, Virgo K, Stein K,
Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, et al:
Cancer treatment and survivorship statistics, 2012. CA Cancer J
Clin. 62:220–241. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fearon ER: Molecular genetics of
colorectal cancer. Annu Rev Pathol. 6:479–507. 2011. View Article : Google Scholar
|
|
4
|
Finkel T, Deng CX and Mostoslavsky R:
Recent progress in the biology and physiology of sirtuins. Nature.
460:587–591. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yuan H, Su L and Chen WY: The emerging and
diverse roles of sirtuins in cancer: A clinical perspective. Onco
Targets Ther. 6:1399–1416. 2013.PubMed/NCBI
|
|
6
|
Chen WY, Wang DH, Yen RC, Luo J, Gu W and
Baylin SB: Tumor suppressor HIC1 directly regulates SIRT1 to
modulate p53-dependent DNA-damage responses. Cell. 123:437–448.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Brunet A, Sweeney LB, Sturgill JF, Chua
KF, Greer PL, Lin Y, Tran H, Ross SE, Mostoslavsky R, Cohen HY, et
al: Stress-dependent regulation of FOXO transcription factors by
the SIRT1 deacetylase. Science. 303:2011–2015. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yu H, Ye W, Wu J, Meng X, Liu RY, Ying X,
Zhou Y, Wang H, Pan C and Huang W: Overexpression of sirt7 exhibits
oncogenic property and serves as a prognostic factor in colorectal
cancer. Clin Cancer Res. 20:3434–3445. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liu C, Huang Z, Jiang H and Shi F: The
sirtuin 3 expression profile is associated with pathological and
clinical outcomes in colon cancer patients. Biomed Res Int.
2014:8712632014.PubMed/NCBI
|
|
10
|
Sebastián C, Zwaans BM, Silberman DM,
Gymrek M, Goren A, Zhong L, Ram O, Truelove J, Guimaraes AR, Toiber
D, et al: The histone deacetylase SIRT6 is a tumor suppressor that
controls cancer metabolism. Cell. 151:1185–1199. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kabra N, Li Z, Chen L, Li B, Zhang X, Wang
C, Yeatman T, Coppola D and Chen J: SirT1 is an inhibitor of
proliferation and tumor formation in colon cancer. J Biol Chem.
284:18210–18217. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
North BJ, Marshall BL, Borra MT, Denu JM
and Verdin E: The human Sir2 ortholog, SIRT2, is an
NAD+-dependent tubulin deacetylase. Mol Cell.
11:437–444. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Vaquero A, Scher MB, Lee DH, Sutton A,
Cheng HL, Alt FW, Serrano L, Sternglanz R and Reinberg D: SirT2 is
a histone deacetylase with preference for histone H4 Lys 16 during
mitosis. Genes Dev. 20:1256–1261. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Das C, Lucia MS, Hansen KC and Tyler JK:
CBP/p300-mediated acetylation of histone H3 on lysine 56. Nature.
459:113–117. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jing E, Gesta S and Kahn CR: SIRT2
regulates adipocyte differentiation through FoxO1
acetylation/deacetylation. Cell Metab. 6:105–114. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jin YH, Kim YJ, Kim DW, Baek KH, Kang BY,
Yeo CY and Lee KY: Sirt2 interacts with 14-3-3 beta/gamma and
down-regulates the activity of p53. Biochem Biophys Res Commun.
368:690–695. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kim HS, Vassilopoulos A, Wang RH, Lahusen
T, Xiao Z, Xu X, Li C, Veenstra TD, Li B, Yu H, et al: SIRT2
maintains genome integrity and suppresses tumorigenesis through
regulating APC/C activity. Cancer Cell. 20:487–499. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Haigis MC, Mostoslavsky R, Haigis KM,
Fahie K, Christodoulou DC, Murphy AJ, Valenzuela DM, Yancopoulos
GD, Karow M, Blander G, et al: SIRT4 inhibits glutamate
dehydrogenase and opposes the effects of calorie restriction in
pancreatic beta cells. Cell. 126:941–954. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nasrin N, Wu X, Fortier E, Feng Y, Bare'
OC, Chen S, Ren X, Wu Z, Streeper RS and Bordone L: SIRT4 regulates
fatty acid oxidation and mitochondrial gene expression in liver and
muscle cells. J Biol Chem. 285:31995–32002. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ahuja N, Schwer B, Carobbio S, Waltregny
D, North BJ, Castronovo V, Maechler P and Verdin E: Regulation of
insulin secretion by SIRT4, a mitochondrial ADP-ribosyltransferase.
J Biol Chem. 282:33583–33592. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jeong SM, Xiao C, Finley LW, Lahusen T,
Souza AL, Pierce K, Li YH, Wang X, Laurent G, German NJ, et al:
SIRT4 has tumor-suppressive activity and regulates the cellular
metabolic response to DNA damage by inhibiting mitochondrial
glutamine metabolism. Cancer Cell. 23:450–463. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Csibi A, Fendt SM, Li C, Poulogiannis G,
Choo AY, Chapski DJ, Jeong SM, Dempsey JM, Parkhitko A, Morrison T,
et al: The mTORC1 pathway stimulates glutamine metabolism and cell
proliferation by repressing SIRT4. Cell. 153:840–854. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tan M, Peng C, Anderson KA, Chhoy P, Xie
Z, Dai L, Park J, Chen Y, Huang H, Zhang Y, et al: Lysine
glutarylation is a protein posttranslational modification regulated
by SIRT5. Cell Metab. 19:605–617. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Du J, Zhou Y, Su X, Yu JJ, Khan S, Jiang
H, Kim J, Woo J, Kim JH, Choi BH, et al: Sirt5 is a NAD-dependent
protein lysine demalonylase and desuccinylase. Science.
334:806–809. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nakagawa T, Lomb DJ, Haigis MC and
Guarente L: SIRT5 deacetylates carbamoyl phosphate synthetase 1 and
regulates the urea cycle. Cell. 137:560–570. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lu W, Zuo Y, Feng Y and Zhang M: SIRT5
facilitates cancer cell growth and drug resistance in non-small
cell lung cancer. Tumour Biol. 35:10699–10705. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Huang G, Cui F, Yu F, Lu H, Zhang M, Tang
H and Peng Z: Sirtuin-4 (SIRT4) is downregulated and associated
with some clinicopathological features in gastric adenocarcinoma.
Biomed Pharmacother. 72:135–139. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Roth M and Chen WY: Sorting out functions
of sirtuins in cancer. Oncogene. 33:1609–1620. 2014. View Article : Google Scholar
|
|
29
|
Cha EJ, Noh SJ, Kwon KS, Kim CY, Park BH,
Park HS, Lee H, Chung MJ, Kang MJ, Lee DG, et al: Expression of
DBC1 and SIRT1 is associated with poor prognosis of gastric
carcinoma. Clin Cancer Res. 15:4453–4459. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Stünkel W, Peh BK, Tan YC, Nayagam VM,
Wang X, Salto-Tellez M, Ni B, Entzeroth M and Wood J: Function of
the SIRT1 protein deacetylase in cancer. Biotechnol J. 2:1360–1368.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Huffman DM, Grizzle WE, Bamman MM, Kim JS,
Eltoum IA, Elgavish A and Nagy TR: SIRT1 is significantly elevated
in mouse and human prostate cancer. Cancer Res. 67:6612–6618. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hida Y, Kubo Y, Murao K and Arase S:
Strong expression of a longevity-related protein, SIRT1, in Bowen's
disease. Arch Dermatol Res. 299:103–106. 2007. View Article : Google Scholar
|
|
33
|
Wang RH, Sengupta K, Li C, Kim HS, Cao L,
Xiao C, Kim S, Xu X, Zheng Y, Chilton B, et al: Impaired DNA damage
response, genome instability, and tumorigenesis in SIRT1 mutant
mice. Cancer Cell. 14:312–323. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Firestein R, Blander G, Michan S,
Oberdoerffer P, Ogino S, Campbell J, Bhimavarapu A, Luikenhuis S,
de Cabo R, Fuchs C, et al: The SIRT1 deacetylase suppresses
intestinal tumorigenesis and colon cancer growth. PLoS One.
3:e20202008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hiratsuka M, Inoue T, Toda T, Kimura N,
Shirayoshi Y, Kamitani H, Watanabe T, Ohama E, Tahimic CG, Kurimasa
A, et al: Proteomics-based identification of differentially
expressed genes in human gliomas: Down-regulation of SIRT2 gene.
Biochem Biophys Res Commun. 309:558–566. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ming M, Qiang L, Zhao B and He YY:
Mammalian SIRT2 inhibits keratin 19 expression and is a tumor
suppressor in skin. Exp Dermatol. 23:207–209. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Dan L, Klimenkova O, Klimiankou M, Klusman
JH, van den Heuvel-Eibrink MM, Reinhardt D, Welte K and Skokowa J:
The role of sirtuin 2 activation by nicotinamide
phosphoribosyltransferase in the aberrant proliferation and
survival of myeloid leukemia cells. Haematologica. 97:551–559.
2012. View Article : Google Scholar :
|
|
38
|
Hou H, Chen W, Zhao L, Zuo Q, Zhang G,
Zhang X, Wang H, Gong H, Li X, Wang M, et al: Cortactin is
associated with tumour progression and poor prognosis in prostate
cancer and SIRT2 other than HADC6 may work as facilitator in situ.
J Clin Pathol. 65:1088–1096. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Jeong SM, Lee A, Lee J and Haigis MC:
SIRT4 suppresses tumor formation in genetic models of Myc-induced B
cell lymphoma. J Biol Chem. 289:4135–4144. 2014. View Article : Google Scholar :
|
|
40
|
Chen J, Zhang B, Wong N, Lo AW, To KF,
Chan AW, Ng MH, Ho CY, Cheng SH, Lai PB, et al: Sirtuin 1 is
upregulated in a subset of hepatocellular carcinomas where it is
essential for telomere maintenance and tumor cell growth. Cancer
Res. 71:4138–4149. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Mathias RA, Greco TM, Oberstein A,
Budayeva HG, Chakrabarti R, Rowland EA, Kang Y, Shenk T and Cristea
IM: Sirtuin 4 is a lipoamidase regulating pyruvate dehydrogenase
complex activity. Cell. 159:1615–1625. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhao Y, Butler EB and Tan M: Targeting
cellular metabolism to improve cancer therapeutics. Cell Death Dis.
4:e5322013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Galluzzi L, Kepp O, Vander Heiden MG and
Kroemer G: Metabolic targets for cancer therapy. Nat Rev Drug
Discov. 12:829–846. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ahmad IM, Abdalla MY, Aykin-Burns N,
Simons AL, Oberley LW, Domann FE and Spitz DR: 2-Deoxyglucose
combined with wild-type p53 overexpression enhances cytotoxicity in
human prostate cancer cells via oxidative stress. Free Radic Biol
Med. 44:826–834. 2008. View Article : Google Scholar
|
|
45
|
Daye D and Wellen KE: Metabolic
reprogramming in cancer: Unraveling the role of glutamine in
tumorigenesis. Semin Cell Dev Biol. 23:362–369. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Tennant DA, Durán RV and Gottlieb E:
Targeting metabolic transformation for cancer therapy. Nat Rev
Cancer. 10:267–277. 2010. View Article : Google Scholar : PubMed/NCBI
|
